Clinical Trial Update: A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del [Phase 2]

View source ↗

Summary

Phase 2 study assessing the impact of Lumacaftor/Ivacaftor on disease progression in young children with cystic fibrosis homozygous for F508del; the study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2021-12-08